Endocrine Abstracts

Background: Mitotane has been used in paliative setting in patients with adrenocortical carcinoma. However, this adrenolytic agent has important toxicities with frequent elevation of cholesterol levels (after a median time of 6 months from mitotane start) and serum aminotransferases. However, there are no published reports of clinically apparent liver injury.Case presentation: We report a case of a 54 year-old man with history of an 11 cm adrenocortical ...

Introduction: Mediastinal paragangliomas are rare. These tumours can be associated with increased morbidity and mortality when invasive growth to the heart, great vessels, esophagus and trachea occurs. Surgical resection, if feasible, is the treatment of choice.Case report: A 50-year-old man presented with severe and refractory left gluteal pain radiating to the posterior thigh for two months. The patient had no relevant medical history and no other symp...

Paragangliomas (PGL) and pheochromocytomas (PHEO) are rare neuroendocrine tumors with an estimated prevalence of 1:6500 and 1:2500, respectively. Although most PGL/PHEO are benign, approximately 10% of PHEOs and 15-35% of PGLs have metastatic disease, which it is main cause of death, with 6 years of median survival. Objective: To characterize the metastatic PHEOs and PGLs from a single center. Methods: Retrospective analysis of clinical records of patients with metastatic PHEO...

Cushing’s syndrome (CS) is associated with a considerable risk of complications including thromboembolic events (TE). They occur mostly within the first 2–3 months postoperatively. When present before surgery, CS has high rates of perioperative mortality and morbidity. The benefit of steroidogenesis inhibitors after TE is not fully known. Furthermore, little guidance is available regarding TE assessment/management in CS. We report a case of a 34-year-old male admitte...

Introduction: the presence of areas with a solid / trabecular growth pattern in differentiated papillary thyroid carcinoma (PTC) represents a source of controversy regarding clinical and prognostic significance and usually requires a more aggressive therapeutic approach. The aim of this study was to compare clinicopathological characteristics, treatments and prognosis of PTC with and without solid component (SC). We also aimed to evaluate whether SC affects patient outcome in ...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Background: Malignant hypercalcemia (MH) occurs in up to 30% of patients who are diagnosed with cancery, being associated with later stages of the disease and poor prognosis. The physiopathological mechanisms responsible for MH are the production of parathyroid hormone-related peptide by the tumor (PTHrp) (80% of cases), osteolytic cytokine production (20%) and excess of 1,25(OH)2vitamin D production (1%).Case report: We present the case of a ...

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...

Introduction: The combination of chemotherapy with prophylatic cranial radiotherapy (C-RT) allowed the improvement of survival rates of pediatric acute lymphoblastic leukemia (ALL) survivors while putting them at risk of develeping long-term endocrine deficiencies, like growth hormone deficiency (GHD).Current evidence suggests that the prevalence of GHD in children treated with radiation doses ≥ 30–50 Gy for non-pituitary brain tumors is...